Diabetes
Conference Coverage
Shelved GLP-1 agonist reduced cardiovascular risk in type 2 diabetes mellitus
Albiglutide reduced the risk of major cardiovascular events by 22%, compared with placebo, in the HARMONY Outcomes trial.
Conference Coverage
Breast cancer risk in type 2 diabetes related to adiposity
Women with type 2 diabetes mellitus have a moderately increased risk of breast cancer that appears to be mainly caused by adiposity, not diabetes...
From the Journals
Online diabetes prevention programs as good as face-to-face programs
An intensive, multifaceted online DPP intervention may be as effective as in-person DPP and help expand reach to those at risk.
Feature
Fish oil phoenix
Feature
Dapagliflozin meets endpoint in top-line DECLARE results, AstraZeneca says
Conference Coverage
GBS in T2DM patients: Study highlights pros and cons, need for better patient selection
Gastric bypass surgery lowers the risk of all-cause mortality and cardiovascular disease, but the risk for a number of short-term complications is...
From the Journals
One-step gestational diabetes screening doesn’t improve outcomes
Revised protocol increased diagnoses, but also increased insulin use and pregnancy outcomes including labor induction and neonatal hyperglycemia...
From the Journals
Elevated type 2 diabetes risk seen in PsA patients
Type 2 diabetes risk was significantly higher among patients with psoriatic arthritis, even when compared with patients with psoriasis alone.
Conference Coverage
Study suggests “alarming” diabetes med discontinuation
ORLANDO – Most type 2 diabetes mellitus patients discontinue their medication within a year.
News
FDA grants praliciguat Fast Track Designation for HFpEF
Enrollment for a phase 2 trial in HFpEF patients continues.
News from the FDA/CDC
CDC: Obesity affects over 35% in 7 states
The number of states with a prevalence of adult obesity of 35% or above went from five in 2016 to seven in 2017.